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Meningococcal diseases are serious threats to global health, and new vaccines speciﬁcally tailored to meet the age-related needs of
variousgeographicalareasarerequired.ThispaperfocusesonthemeningococcalconjugatevaccinesdevelopedbyGSKBiologicals.
Two combined conjugate vaccines were developed to help protect infants and young children in countries where the incidence of
meningococcal serogroup C or serogroup C and Y disease is important: Hib-MenC-TT vaccine, which oﬀers protection against
Haemophilus inﬂuenzae type b and Neisseria meningitidis serogroup C diseases, is approved in several countries; and Hib-MenCY-
TT vaccine, which adds N. meningitidis serogroup Y antigen, is currently in the ﬁnal stages of development. Additionally, a
tetravalent conjugate vaccine (MenACWY-TT) designed to help protect against four meningococcal serogroups is presently being
evaluated for global use in all age groups. All of these vaccines were shown to be highly immunogenic and to have clinically
acceptable safety proﬁles.
1.Introduction
Invasive diseases caused by Neisseria meningitidis,o fw h i c h
meningitis and septicaemia are the most important, are se-
rious threats to global health [1, 2]. Sporadic as well as en-
demic cases occur worldwide, and N. meningitidis is the only
encapsulated bacterium known to cause large epidemics of
bacterial meningitis [3, 4]. Notably, extensive meningococcal
diseaseoutbreakscomprisinghundredsofthousandsofcases
occur cyclically in an area of Sub-Saharan Africa, also called
the Meningitis Belt [5–8]. Overall, about 500,000 cases of
meningococcaldiseaseoccureachyearcausingatleast50,000
deaths [9]. Meningococcal meningitis has a case-fatality rate
of 5% to 10% in industrialised countries, which can reach
20% in the developing world [10, 11]. In addition, 12% to
19% of survivors develop long-term neurological sequelae
[3, 7, 12–14]. While the highest case-fatality rate is observed
among persons older than 65years and generally decreases
with lower age [10], the risk of meningococcal disease is
highest in infants and young children with a secondary peak
in incidence during adolescence and young adulthood [15].
N. meningitidis is a gram-negative encapsulated diplo-
coccus that colonises the human nasopharynx, where it
is usually carried asymptomatically [1]. Meningococci are
transmitted through close contact via respiratory droplets
[7]. In some cases, bacteria spread from the nasopharynx
to nearby epithelial cells causing local invasion of tissue. If
the meningococci reach the bloodstream, they may cause
meningococcal meningitis or fulminant septicaemia [3, 7,
16]. N. meningitidis is classiﬁed into 13serogroups according
to diﬀerences in the capsular polysaccharide (PS) antigens.
Six of these serogroups (A, B, C, W-135, Y, and more recently
X) are responsible for the majority of meningococcal disease
cases [3, 17].
Meningococcal incidence and serogroup distribution are
highly regional and have a cyclical nature, with peaks typi-
cally occurring in a ﬁve-to-eight-year pattern [18, 19]. For
this reason, meningococcal disease surveillance is required
for the assessment of local epidemiology and disease burden,
which are key issues for vaccine formulation and prevention
strategies [19]. Although many of the surveillance systems2 Advances in Preventive Medicine
for meningococcal disease lack sensitivity and may under-
estimate disease burden, current meningococcal disease epi-
demiology can be summarised per region [19]. In Africa and
Asia, serogroup A (MenA) remains the cause of most large-
scale epidemics, with the highest magnitude in the African
Meningitis Belt, while serogroups B and C (MenB and
MenC)areassociatedwithsporadicdisease[3,19–21].Inad-
dition, serogroup W-135 (MenW-135) has emerged as a new
threat after causing outbreaks in Hajj pilgrims in Saudi
Arabia, followed by Burkina Faso and Chad [22, 23]. More
recently,variousoutbreaksduetoserogroupXhavealsobeen
reported in Africa [24–26]. In industrialised countries such
as Europe, the United States (USA), Latin America and Aus-
tralia, MenB and MenC are the most important causes of
invasive meningococcal disease [2, 14, 19, 27–29]. In addi-
tion, serogroup Y (MenY) accounts for around one-third of
meningococcal disease cases in the US and the incidence of
this serogroup has also recently increased in Scandinavian
countries [10, 14, 17, 30]. In industrialised countries, rates
of meningococcal disease are presently very low (0.5–6 per
100,000 population) and this may be explained by a com-
bination of environmental, organism and host factors. Even
with this historically low rate, meningococcal disease contin-
ues to cause considerable morbidity and mortality among all
age groups in these regions and N. meningitidis remains the
most common cause of bacterial meningitis in children and
young adults [2, 10].
While mass chemoprophylaxis is not recommended to
control large outbreaks of meningococcal disease, vaccina-
tion is considered to be an eﬀective prevention strategy and
the development of eﬀective meningococcal vaccines, which
have acceptable safety proﬁles, is a public health priority
[31, 32]. The ﬁrst vaccines developed were plain PS vaccines
that consist of puriﬁed capsular PS from speciﬁc menin-
gococcalserogroups.GlaxoSmithKline(GSK)Biologicalsde-
veloped diﬀerent formulations of plain PS vaccines against
serogroups A, C, W-135, and Y (MencevaxAC, Mencevax-
ACW, MencevaxACWY). These vaccines have been used to
immunise travellers, Hajj pilgrims, military personnel, and
other speciﬁc populations at increased risk for invasive men-
ingococcal disease [33, 34]. Meningococcal PS vaccines are
available for use in children above two years of age but, aside
from the PS from MenA, which is immunogenic in infants
as young as three months of age, they are suboptimally im-
munogenic and therefore not indicated in infants and tod-
dlers [35, 36]. Moreover, PS vaccines induce T-cell-inde-
pendent immune responses, which are not longlasting, do
not result in immune memory and can induce immuno-
logical hyporesponsiveness for serogroups A, C, W-135, and
Y. For these reasons, PS vaccines are not appropriate when
sustained protection is needed [37–40].
To overcome these limitations, conjugate vaccines were
developed, in which capsular PS are covalently coupled to
carrier proteins that contain T-cell epitopes. These vaccines
have been shown to be immunogenic in infants, T-cell de-
pendent, induce immune memory, and induce higher bac-
tericidal titres, which potentially could translate into longer
antibody persistence [37, 38, 41]. The most common carrier
proteins used in conjugate meningococcal vaccines are
tetanus toxoid (TT), diphtheria toxoid (DT), and a nontoxic
cross-reacting mutant of DT (CRM197)[ 38]. Conjugate
vaccines against MenC were introduced in 1999 in the
United Kingdom (UK) as part of a vaccination programme
that included routine infant immunisation and a large-scale
catch-up campaign from infants through children 18years of
age, which was later extended to 24years of age. This pro-
gramme had a tremendous impact on the incidence of the
disease and induced herd immunity [42–44]. MenC vacci-
nation programmes have been successfully implemented in
other countries as well, including Canada, Spain, and the
Netherlands [45–47]. Presently, two tetravalent conjugate
vaccines against serogroups A, C, W-135, and Y, using DT or
CRM197 as carrier proteins, have been licensed in various
countries.
Unlike other meningococcal serogroups (A, C, W-135,
and Y), capsular PS from MenB is poorly immunogenic in
humans. Furthermore, the capsular structure of MenB mim-
ics sialylated structures in human neural tissue posing po-
tential safety concerns for a vaccine formulation containing
these polymers. Therefore, most of the MenB vaccine re-
search has been focused on the outer membrane proteins
(OMPs) [48]. MenB vaccines have been developed using al-
ternative strategies and they are available in Cuba, New
Zealand, the Netherlands, and France [29]. However, these
vaccines are strain speciﬁc and therefore their use is limited
[49]. A protein-based investigational MenB vaccine intended
for global use has been developed by Novartis, and a Mar-
keting Authorization Application was submitted to the Euro-
pean Medicines Agency (EMA) at the end of 2010. A second
investigational protein-based MenB vaccine being developed
by Pﬁzer is currently in Phase II of clinical development.
In this paper, we will focus on vaccines, developed by
GSK Biologicals, against the most common serogroups for
which PS conjugate vaccine technology can be used (MenA,
MenC, MenW-135, and MenY). The vaccine development
strategy was driven by the populations at highest risk: ﬁrst
the developing world with a focus on Africa, then more in-
dustrialised countries with a focus on the highest risk pop-
ulations (infants and young children, followed by adoles-
cents).Thesevaccineshavebeenstudiedinrandomised,con-
trolled clinical trials evaluating the immunogenicity, anti-
body persistence, induction of immune memory, reacto-
genicity, and safety of the diﬀerent vaccines. Results of the
studies that are discussed here have been previously pre-
sented in peer-reviewed publications (Table 1).
2. Conjugate Meningococcal Vaccines
DevelopedbyGSKBiologicals
The eﬀectiveness of meningococcal vaccines is challenging to
evaluate in prospective, randomised eﬃcacy studies because
the incidence of endemic meningococcal disease is low, and
epidemics are diﬃcult to predict. Therefore, eﬃcacy is in-
ferred from immunogenicity data via laboratory markers
thatcanreliablypredictclinicalprotection[50].Theprimary
human defence to meningococcus is the activation of the
complement system by antigen-speciﬁc antibodies resultingAdvances in Preventive Medicine 3
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Table 5: rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody response one month [87, 91]o r4 2d a y s[ 90]a f t e ro n ed o s e
of MenACWY-TT in toddlers (ATP immunogenicity cohort).
Reference Age group Vaccine N % ≥1:8 [95% CI] % ≥1:128 [95% CI] GMT [95% CI]
rSBA-MenA
Knuf et al., 2010
[87]
12–14months MenACWY-TT 42 100 [91.6–100] 100 [91.6–100] 5665.2 [4086.0–7854.9]
Vesikari et al., 2011
[90]
12–23months MenACWY-TT 354 99.7 [98.4–100] 99.7 [98.4–100] 2205.0 [2007.8–2421.6]
MenACWY-TT +
MMRV
360 100 [99.0–100] 99.7 [98.5–100] 2085.9 [1905.3–2283.6]
Knuf et al., 2011
[91]
12–23months
MenACWY-TT 183 98.4 [95.3–99.7] 97.8 [94.5–99.4] 3169.9 [2577.2–3898.8]
MenACWY-TT∗ 178 100 [97.9–100] 100 [97.9–100] 1938.3 [1699.1–2211.2]
MenACWY-TT +
DTPa-HBV-
IPV/Hib
193 100 [98.1–100] 100 [98.1–100] 3152.9 [2752.5–3611.4]
rSBA-MenC
Knuf et al., 2010
[87]
12–14months MenACWY-TT 42 100 [91.6–100] 95.2 [83.8–99.4] 983.5 [718.7–1345.9]
MenC-CRM197 46 97.8 [88.5–100] 87.0 [73.7–95.1] 372.5 [257.7–538.4]
Vesikari et al., 2011
[90]
12–23months
MenACWY-TT 354 99.7 [98.4–100] 95.8 [93.1–97.6] 477.6 [437.3–521.6]
MenACWY-TT +
MMRV
357 100 [99.0–100] 94.4 [91.5–96.5] 519.0 [470.9–571.9]
MenC-CRM197 121 97.5 [92.9–99.5] 70.2 [61.3–78.2] 212.3 [170.0–265.2]
Knuf et al., 2011
[91]
12–23months
MenACWY-TT 183 97.3 [93.7–99.1] 94.0 [89.5–97.0] 828.7 [672.4–1021.4]
MenACWY-TT∗ 178 100 [97.9–100] 88.2 [82.5–92.5] 386.0 [333.9–446.2]
MenACWY-TT +
DTPa-HBV-
IPV/Hib
191 100 [98.1–100] 99.0 [96.3–99.9] 879.7 [763.1–1014.0]
MenC-CRM197 114 98.2 [93.8–99.8] 89.5 [82.3–94.4] 691.4 [520.8–917.9]
rSBA-MenW-135
Knuf et al., 2010
[87]
12–14months MenACWY-TT 43 100 [91.8–100] 100 [91.8–100] 3975.2 [3065.7–5154.5]
Vesikari et al., 2011
[90]
12–23months MenACWY-TT 354 100 [99.0–100] 99.4 [98.0–99.9] 2681.7 [2453.1–2931.6]
MenACWY-TT +
MMRV
360 100 [99.0–100] 100 [99.0–100] 2055.8 [1871.0–2258.9]
Knuf et al., 2011
[91]
12–23months
MenACWY-TT 186 98.4 [95.4–99.7] 96.8 [93.1–98.8] 4022.3 [3269.2–4948.8]
MenACWY-TT∗ 179 100 [98.0–100] 99.4 [96.9–100] 2466.4 [2175.4–2796.4]
MenACWY-TT +
DTPa-HBV-
IPV/Hib
193 100 [98.1–100] 100 [98.1–100] 4147.0 [3670.1–4685.8]
rSBA-MenY
Knuf et al., 2010
[87]
12–14months MenACWY-TT 42 100 [91.6–100] 100 [91.6–100] 2295.1 [1701.5–3095.8]
Vesikari et al., 2011
[90]
12–23months MenACWY-TT 354 100 [99.0–100] 99.7 [98.4–100] 2729.4 [2472.7–3012.8]
MenACWY-TT +
MMRV
359 100 [99.0–100] 99.7 [98.5–100] 2282.4 [2051.3–2539.5]
Knuf et al., 2011
[91]
12–23months
MenACWY-TT 185 97.3 [93.8–99.1] 96.2 [92.4–98.5] 3167.7 [2521.9–3978.9]
MenACWY-TT∗ 179 99.4 [96.9–100] 99.4 [96.9–100] 2446.9 [2088.5–2866.8]
MenACWY-TT +
DTPa-HBV-
IPV/Hib
192 100 [98.1–100] 100 [98.1–100] 3461.8 [2990.1–4007.9]
N: numbers of subjects with available data, %: percentage of subjects with titre within the speciﬁed range, 95% CI: 95% conﬁdence interval, GMT: Geometric
Mean Titre, ∗MenACWY-TT given one month after DTPa-HBV-IPV/Hib vaccine, Results of this table were previously published [87, 90, 91].10 Advances in Preventive Medicine
Table 6: rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody response one month after MenACWY-TT vaccination in
children and adolescents (ATP immunogenicity cohort).
Reference Age group Vaccine N VRR [95% CI] N GMT [95% CI]
rSBA-MenA
Østergaard et al., 2009 [86] 15–19years MenACWY-TT 23 87.0 [66.4–97.2] 24 9264 [6342–13532]
ACWY-PS 23 78.3 [56.3–92.5] 25 8284 [6035–11370]
Knuf et al., 2010 [87] 3–5years MenACWY-TT 40 92.5 [79.6–98.4] 49 8299.4 [6734.2–10228.4]
ACWY-PS 31 80.6 [62.5–92.5] 33 3798.4 [2888.9–4994.2]
Bermal et al., 2011 [88] 11–17years MenACWY-TT 615 85.4 [82.3–88.1] 752 6106.8 [5739.5–6497.6]
ACWY-PS 215 79.5 [73.5–84.7] 252 3203.0 [2854.1–3594.6]
rSBA-MenC
Østergaard et al., 2009 [86] 15–19years MenACWY-TT 24 95.8 [78.9–99.9] 24 4329 [2404–7795]
ACWY-PS 24 91.7 [73.0–99.0] 25 1567 [757–3245]
Knuf et al., 2010 [87] 3–5years MenACWY-TT 47 93.6 [82.5–98.7] 49 1577.8 [1123.5–2215.9]
ACWY-PS 32 81.3 [63.6–92.8] 34 445.4 [263.3–753.3]
Bermal et al., 2011 [88] 11–17years MenACWY-TT 719 97.1 [95.6–98.2] 754 12645.5 [11531.8–13866.7]
ACWY-PS 237 96.6 [93.5–98.5] 252 8271.6 [6937.3–9862.4]
rSBA-MenW-135
Østergaard et al., 2009 [86] 15–19years MenACWY-TT 23 91.3 [72.0–98.9] 24 4422 [2939–6653]
ACWY-PS 25 96.0 [79.6–99.9] 25 3486 [2447–4967]
Knuf et al., 2010 [87] 3–5years MenACWY-TT 47 100 [92.5–100] 49 5987.2 [4846.9–7395.7]
ACWY-PS 32 96.9 [83.8–99.9] 34 1811.1 [1233.3–2659.5]
Bermal et al., 2011 [88] 11–17years MenACWY-TT 717 96.5 [94.9–97.7] 759 8390.1 [7777.8–9050.7]
CWY-PS 242 88.0 [83.2–91.8] 252 2679.3 [2363.7–3037.2]
rSBA-MenY
Østergaard et al., 2009 [86] 15–19years MenACWY-TT 24 79.2 [57.8–92.9] 24 2756 [2023–3755]
ACWY-PS 25 88.0 [68.8–97.5] 25 3056 [1892–4937]
Knuf et al., 2010 [87] 3–5years MenACWY-TT 48 100 [92.6–100] 49 6433.0 [4921.0–8409.6]
ACWY-PS 34 79.4 [62.1–91.3] 34 1435.5 [972.6–2118.7]
Bermal et al., 2011 [88] 11–17years MenACWY-TT 737 93.1 [91.0–94.8] 758 13865.2 [12968.1–14824.4]
ACWY-PS 246 78.0 [72.3–83.1] 252 5245.3 [4644.2–5924.1]
N: numbers of subjects with available data, 95% CI: 95% conﬁdence interval, GMT: geometric mean titre, VRR: vaccine response rate, Vaccine response
deﬁned as: (1) for initially seronegative subjects, antibody titres ≥1:32 at one month after vaccination, (2) for initially seropositive subjects, antibody titres at
one month after vaccination ≥4-fold the pre-vaccination antibody titre, Results of this table were previously published [86–88].
Table 7: Percentage of subjects with hSBA titres ≥1:8 and hSBA GMTs against serogroups A, C, W-135, and Y at 42 days after one dose of
MenACWY-TT in toddlers (ATP immunogenicity cohort).
Vaccine N % ≥ 1:8 [95% CI] GMT [95% CI]
hSBA-MenA
MenACWY-TT 338 77.2 [72.4–81.6] 19.0 [16.4–22.1]
MenACWY-TT + MMRV 348 83.9 [79.6–87.6] 33.7 [28.9–39.2]
hSBA-MenC
MenACWY-TT 341 98.5 [96.6–99.5] 196.0 [175.4–219.0]
MenACWY-TT + MMRV 346 98.0 [95.9–99.2] 209.1 [183.8–238.0]
MenC-CRM197 116 81.9 [73.7–88.4] 40.3 [29.5–55.1]
hSBA-MenW-135
MenACWY-TT 336 87.5 [83.5–90.8] 48.9 [41.2–58.0]
MenACWY-TT + MMRV 337 82.8 [78.3–86.7] 57.3 [47.0–69.9]
hSBA-MenY
MenACWY-TT 329 79.3 [74.5–83.6] 30.9 [25.8–37.1]
MenACWY-TT + MMRV 333 81.4 [76.8–85.4] 38.7 [32.2–46.7]
N: numbers of subjects with available data, %: percentage of subjects with titre within the speciﬁed range, 95% CI: 95% conﬁdence interval, GMT: Geometric
Mean Titre, Results of this table were previously published [90].Advances in Preventive Medicine 11
in bacterial lysis. Bactericidal assays measuring interactions
ofantibodiesandhumancomplementatthebacterialsurface
(hSBA) can be used to measure the functional activity of a
tested serum against a given strain of meningococcus. Data
generated in US military recruits suggested that an hSBA
titre ≥1:4 correlated with protection against meningococcal
serogroup C disease [51]. After introduction of MenC con-
jugate vaccines in the UK another serological correlate of
protection based on a serum bactericidal assay using rabbit
complement (rSBA titre ≥1:8) became available using both
prelicensure age-stratiﬁed seroprevalence and disease inci-
dence data, and postlicensure eﬃcacy estimates [52–54]. The
seroprotective thresholds for MenC have been extended to
serogroups A, W-135, and Y. Both assays are accepted by the
WHO for the assessment of the immunogenicity of men-
ingococcal vaccines [55] and both have been used in GSK’s
clinical development depending on regional health authority
requirements.
2.1. DTPw-HBV/Hib-MenAC Combined Vaccine for African
Infants. In Africa, the world’s highest risk population, PS
vaccines against meningococcal disease are available but they
do not oﬀer broad serogroup protection to infants and in
older subjects they only protect for 3–5years, leaving the
population vulnerable to future epidemics [56–58]. More-
over, the hyporesponsiveness that may be induced by repeat-
ed injections of PS vaccines compromises their use in the fu-
ture because the population remains at life-long risk for in-
vasive meningococcal disease [37].
In2000,theWHOandrepresentativesfromeightAfrican
countries called for the development of new conjugate vac-
cines, which could be used in routine vaccination campaigns
to control invasive meningococcal disease in Africa. In re-
sponse to this request, GSK Biologicals initiated the devel-
opment of a new heptavalent diphtheria, tetanus, whole cell
pertussis,hepatitisB,Haemophilusinﬂuenzaetypeb,N.men-
ingitidis serogroups A, and C- tetanus toxoid conjugate com-
bined vaccine (DTPw-HBV/Hib-MenAC-TT) intended for
vaccination of infants [59–61]. Indeed, MenA and to a lesser
extent MenC contribute to endemic disease and periodic
outbreaks in Africa and at that time, MenW-135 was not yet
recognised as an important serogroup in the African Menin-
gitis Belt [22, 23]. The addition of antigens from MenA and
MenC to antigens of vaccines routinely administered in pae-
diatric vaccination programmes was intended to promote
rapiduptakeandhighcoverageofthesecomponentswithout
the need for further vaccination visits or injections, while
minimising costs [62–64].
Three-dose primary vaccination with DTPw-HBV/Hib-
MenAC-TTwasshowntobenoninferiortoDTPw-HBV/Hib
forthe ﬁve commonantigens and induced antibodies against
MenA and MenC in the majority of subjects when given to
Africaninfantsat6,10,and14weeksofage[60].Thevaccine
induced a good persistence of antibodies and immune mem-
ory [59]. As for other conjugate vaccines used in infancy
[52,65,66],aboosterdosewasrequiredinthesecondyearof
life to sustain protection through early childhood [60]. The
DTPw-HBV/Hib-MenAC-TTvaccinehadaclinicallyaccept-
able safety proﬁle and no speciﬁc safety issues were raised
during the Phase II and Phase III studies [59–61]. No in-
crease in reactogenicity during the primary vaccination
course was observed when compared with the licensed
DTPw-HBV/Hib vaccines [59].
Following development of this new vaccine, the WHO
communicated that they were prioritising mass vaccination
inolderindividualsandforMenAonly,sincethisiscurrently
the predominant serogroup in the African Meningitis Belt.
As DTPw-HBV/Hib-MenAC-TT was a combination vaccine
designed to be incorporated into the routine vaccination
schedule for younger children, ﬁnal development of the vac-
cine was stopped following consultation with the WHO. Re-
cently, a new MenA conjugate vaccine (MenAfriVac, the Se-
rum Institute of India) was licensed and prequaliﬁed by the
WHO. However, this new vaccine will only provide protec-
tion against MenA and there may be need in the future for
conjugate vaccines directed against other serogroups.
2.2. Hib-MenC-TT Combined Vaccine for Infants: Menitorix.
The next high-risk population targeted by GSK Biologicals
for the development of conjugate vaccines were infants and
young children in countries where MenC is the predominant
serogroup, since these age groups are at the highest risk for
invasive disease in most countries worldwide [2, 10, 19]. As
thelistofrecommendedvaccinestobeincludedinchildhood
immunisation programmes increases, combination vaccines
have been recognised as a means of simplifying immunisa-
tion schedules [62–64]. Therefore, GSK Biologicals initiated
the development of a combined vaccine (Hib-MenC-TT) in-
tended to provide protection to infants and toddlers against
twomajorpathogensresponsibleforbacterialmeningitis(H.
inﬂuenzae type b [Hib] and N. meningitidis serogroup C
[MenC]). The Hib-MenC-TT vaccine oﬀers an alternative
vaccination schedule to the acellular pertussis (DTPa)-Hib
combinations coadministered with standalone MenC conju-
gate vaccines [67].
Hib-MenC-TT contains 5µg polyribosylribitol phos-
phate (PRP) from Hib and 5µg PS from MenC, each con-
jugated to TT. Phase II and Phase III studies have shown that
the Hib-MenC-TT vaccine is immunogenic when adminis-
tered as three-dose primary series in infants at 2, 3, and 4
months of age [68–70]o ra t2 ,4 ,a n d6m o n t h so fa g e[ 62,
71]( Table 2). At least 98.8–100% of subjects had anti-PRP
≥0.15µg/mL (data not shown) and 99.2–100% had rSBA-
MenC titres ≥1:8(Table 2) after completion of the primary
vaccination schedule. The Hib-MenC-TT combined vaccine
induced MenC and Hib responses comparable to those in-
duced by licensed monovalent vaccines and all primary hy-
potheses regarding the noninferiority of Hib-MenC-TT to
licensed Hib and monovalent MenC conjugate were met
[62, 68, 70, 72]. Consistently high anti-PRP GMCs were ob-
served across the studies, suggesting that Hib-MenC-TT can
overcome the challenges seen with reduced Hib immuno-
genicity when Hib conjugate vaccines are given in combi-
nation with acellular pertussis compared with separate in-
jections [67].
Moreover, primary vaccination with Hib-MenC-TT in-
duced persistent antibodies against both antigens up to the
second year of life [68, 70, 73, 74]. The immune response12 Advances in Preventive Medicine
postvaccination and the persistence of anti-PRP antibodies
up to the booster vaccination was higher following vacci-
nation with Hib-MenC-TT than following vaccination with
DTPa/Hib combined vaccines [73, 74]. Moreover, the per-
sistence of rSBA-MenC antibodies, when measured before
booster vaccination, was higher in subjects primed with
Hib-MenC-TT than in subjects primed with MenC-CRM197
although lower than in subjects primed with MenC-TT [73,
74].
The booster dose administered in the second year of life
resulted in very high seroprotection rates against both Hib
a n dM e n C[ 68, 71, 73–75]( Table 2). After the booster vac-
cination, the percentages of Hib-MenC-TT primed children
with anti-PRP ≥1.0µg/mL and rSBA-MenC titres ≥1:128
were 100% (data not shown) and 97.4–100% (Table 2), re-
spectively. Long-term persistence of the immune response
induced by the booster was observed up to two years after
vaccination [76]. The totality of the clinical data collected
demonstrated that Hib-MenC-TT can be used as booster
dose for toddlers previously primed with MenC and Hib in
infancy [72–74]. Of note, the noninferiority of Hib-MenC-
TT to monovalent Hib and MenC conjugate vaccines was
demonstrated when administered as a single dose in Hib-
primed but MenC-na¨ ıve toddlers [72]. The evaluation of
the persistence of the Hib and MenC immunogenicity after
diﬀerent vaccination schedules is ongoing for up to ﬁve years
postbooster vaccination.
In addition, one booster dose of Hib-MenC-TT, given to
children aged 6–12 years who were primed six years before
with MenC-CRM197, was shown to be highly eﬀective and
rSBA-MenC antibody titres ≥1:8 were sustained for at least
oneyearin99.6%ofthevaccines[77].However,theseresults
were somewhat contradictory with other studies showing
reduced postbooster responses and antibody persistence
when MenC-CRM197 was used for priming, regardless of
whether a CRM197 or a TT conjugate vaccine was used for
boosting [78, 79].
Notably, no evidence of negative interference on the im-
mune response to any of the antigens was observed when the
Hib-MenC-TT vaccine was coadministered with common
childhood vaccines including combined measles, mumps,
and rubella vaccine [MMR], combined diphtheria, tetanus,
acellular pertussis, and inactivated polio vaccine [DTPa-
IPV], a combined diphtheria-tetanus-acellular pertussis-
hepatitis B-inactivated poliovirus vaccine [DTPa-HBV-IPV],
a 7-valent pneumococcal conjugate vaccine (7vCRM) and a
10-valent pneumococcal nontypeable H. inﬂuenzae protein
D-conjugate vaccine [PHiD-CV] [62, 69, 71, 75, 80].
In reported studies, a total of 3127children less than two
years were vaccinated with Hib-MenC-TT combined vac-
cine. In primary and booster studies, Hib-MenC-TT was
comparable to control monovalent Hib and MenC vaccines
in term of local reactogenicity (pain, redness, and swelling)
and general solicited symptoms (fever, irritability/fussiness,
drowsiness, and loss of appetite), with some evidence of low-
er rates of fever. The clinical studies supported the accept-
ability of the safety proﬁle of Hib-MenC-TT.
In the UK, Hib-MenC-TT has been used as booster vac-
cination for the Hib and MenC antigens in the second year
of life (after monovalent MenC and DTPa/Hib priming in
infants) since September 2006. The vaccine is currently ap-
proved in some EU countries, in Brazil, and in New Zealand
for three-dose primary vaccination in infants from the age
of two months up to 12months and for booster vaccination
in toddlers up to the age of two years. The vaccine is also
approved in Australia for one-dose vaccination in toddlers
previously primed with Hib but na¨ ıve for MenC [72].
In summary, Hib-MenC-TT was shown to be immuno-
genic with an acceptable safety proﬁle when given to infants
and toddlers. Primary vaccination resulted in immune prim-
ing and the induction of immune memory as reﬂected by
antibody persistence and response to booster vaccination.
The consistent observation of signiﬁcantly higher anti-PRP
GMCs versus control vaccines suggests that placing the Hib
antigen in combination with meningococcal antigens can
overcome the reduction in Hib immunogenicity noted in
combination vaccines including Hib and acellular pertussis
antigens [67].
2.3. Investigational Hib-MenCY-TT Combined Vaccine for
Infants. Unlike inmost otherindustrialised countries,MenY
is also a major cause of meningococcal disease in the USA,
where MenC and MenY together account for approximately
two-thirds of invasive disease [10, 92]. In addition, this sero-
group has more recently also been noticed in other regions,
including Europe [30]. For this reason, GSK Biologicals is
developing an investigational combination vaccine (Hib-
MenCY-TT) designed to protect infants and toddlers against
invasive diseases caused by MenC, MenY, and Hib. This vac-
cine has been investigated according to a four-dose immu-
nisation series at 2, 4, 6, and 12–15months or 2, 3, 4, and
12–18months. The 2, 4, 6, and 12–15months schedule was
studied because this is the currently recommended Advisory
Committee on Immunization Practices schedule for routine
Hib conjugate in the USA. Serogroup Y has been included in
theinvestigational combination vaccinebecauseserogroup Y
causes approximately 1/3 of invasive meningococcal disease
in the USA [10].
A single dose of Hib-MenCY-TT contains 2.5µgP R P
from Hib and 5µge a c ho fP Sf r o mM e n Ca n dM e n Y ,a l l
conjugated to TT. In Phase II studies, Hib-MenCY-TT was
shown to be immunogenic for all three antigens after three-
dose vaccination at 2, 3, and 4months [68]o r2 ,4 ,a n d6
months [81, 82, 84] of age and after a fourth dose at 12–
18 months of age [68, 83, 84]( T a b l e s3 and 4). All pri-
mary hypotheses regarding the noninferiority of Hib-
MenCY-TTtolicensedHibandmonovalentMenCconjugate
vaccines were met, and as with the Hib-MenC-TT vaccine,
consistently higher anti-PRP concentrations were observed
with Hib-MenCY-TT than with licensed Hib conjugate vac-
cines [68, 82, 84]. In addition, vaccination of infants with
Hib-MenCY-TTinducedanimmuneresponseagainstMenC
and MenY that was signiﬁcantly higher than that induced by
one injection of a licensed tetravalent polysaccharide vaccine
in older children [82]. The antibody persistence of the fourth
dose was shown for at least one year [83].
More recently, a Phase III study conducted in the USA,
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highly immunogenic to the meningococcal antigens and that
the immune response induced by this vaccine in terms of
anti-PRP concentrations was noninferior to that induced by
licensed Hib vaccines when used according to the 2, 4, 6, and
12–15months schedule [85].
Clinical data for the investigational Hib-MenCY-TT vac-
cine did not indicate interference with common childhood
vaccines including DTPa-HBV-IPV, 7vCRM, MMR, and a
varicella vaccine [81, 82]. The lack of immune interference
with these antigens that are established in paediatric vacci-
nation schedules is critical for the successful incorporation
of the novel antigens.
The reactogenicity and safety proﬁle of Hib-MenCY-TT
was shown to be clinically acceptable in infants and toddlers
whoreceivedfourconsecutivedosesofthisvaccinecoadmin-
isteredwithroutinelyrecommendedpaediatricvaccines.The
reactogenicity proﬁle of Hib-MenCY-TT was similar to that
of Hib-TT, Hib-OMP and MenC-CRM197 and the incidence
of grade 3symptoms was low in all the studies [68, 81–85].
In summary, Hib-MenCY-TT was shown to be immuno-
genic to the Hib and the meningococcal serogroup C and
Y components when given to infants and toddlers as four-
dose immunisation series. Hib-MenCY-TT was noninferior
to licensed monovalent control vaccines and demonstrated
a clinically acceptable safety proﬁle. An application for
licensure of this vaccine was submitted to the US Food
and Drug Administration (FDA) on August 12, 2009 and
is currently under review. Hib-MenCY-TT is not currently
licensed in any country.
2.4. Investigational MenACWY-TT Conjugate Vaccine for All
Age Groups. Besides infants and young children, adolescents
are the second key age group at increased risk for meningo-
coccal disease. Accordingly, GSK Biologicals is developing
a new investigational tetravalent meningococcal conjugate
vaccine with PS from serogroups A, C, W-135, and Y conju-
gated to TT (MenACWY-TT) to complement the two other
tetravalent conjugate vaccines that are currently available.
Indeed, as previously discussed, primary vaccination with a
MenC-TT vaccine has been demonstrated to result in higher
rSBA-MenC titres as compared to priming with either of the
two monovalent MenC conjugate vaccines that use CRM197
as carrier protein, translating into higher persistence up to
one year after booster, regardless of the booster vaccine
used [78, 79, 93]. Unlike Hib-MenC-TT and Hib-MenCY-
TT, MenACWY-TT is not only intended for vaccination of
infants and toddlers and therefore Hib was not included
as a component of the vaccine. Although the MenACWY-
TT vaccine was developed with a focus on adolescents, the
investigational vaccine is being evaluated in various age
groups including infants (NCT01144663).
Phase II and phase III studies showed that a single
dose of MenACWY-TT was highly immunogenic in toddlers,
children, adolescents and adults at one month following vac-
cination (Tables 5, 6 and 7). The observed rSBA and hSBA
GMTs against MenC were signiﬁcantly higher following
MenACWY-TT vaccination in toddlers in the second year of
life when compared to vaccination with a licensed serogroup
C conjugate vaccine (MenC-CRM197)[ 87, 90, 91]. Recent
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Figure 1: Vaccine response for hSBA antibodies one month
after vaccination with MenACWY-TT or with a control vaccine
in subjects aged 11–25years (ATP cohort for immunogenic-
ity). (MenACWY-TT: subjects vaccinated with MenACWY-TT,
MenACWY-DT: subjects vaccinated with MenACWY-DT, vaccine
response deﬁned as (1) for initially seronegative subjects, antibody
titres ≥1:16 at one month after vaccination, (2) for initially sero-
positivesubjects,antibodytitresatonemonthaftervaccination ≥4-
fold the prevaccination antibody titre. Error bars represent the 95%
conﬁdence interval. ∗Statistically signiﬁcantly higher value in the
ACWY-TT group compared to the ACWY-DT group (exploratory
analysis). Results of this ﬁgure are currently in publication [89].)
studies have shown that MenACWY-TT did not interfere
withDTPa-HBV-IPV/HiboracombinedMMRandvaricella
vaccine (MMRV) in toddlers, nor did it aﬀect the safety pro-
ﬁle of these vaccines [90, 91]. In children [87], adolescents
[88], and young adults [86], exploratory analyses showed
that MenACWY-TT induced statistically signiﬁcantly higher
rSBA GMTs for all serogroups compared to a licensed tet-
ravalent plain PS vaccine. In the study conducted in subjects
aged 11–17years, noninferiority of MenACWY-TT to the
licensed tetravalent PS vaccine was demonstrated in terms
of percentage of subjects with a vaccine response [88]. In
addition, a recent study showed that the proportion of sub-
jectswithavaccineresponseandthehSBAGMTswerehigher
after vaccination with MenACWY-TT than with a licensed
tetravalent diphtheria toxoid conjugate vaccine (MenACWY-
DT) (Figure 1)[ 89].
Overall, MenACWY-TT was shown to have increased
reactogenicity as compared to plain PS vaccines in children,
adolescents, and adults and to have a similar reactogenicity
proﬁle compared to conjugate vaccines: MenC-CRM197 in
toddlers younger than two years and MenACWY-DT in ado-
lescents [86–91]. These results were expected as conjugate
vaccines are known to be more reactogenic than PS vaccines
and similar ﬁndings were observed with a PS vaccine com-
pared to MenACWY-DT and MenACWY-CRM197 [94, 95].
Given the relatively infrequent reports of grade 3symptoms
(≤9.3% of subjects [87]), the MenACWY-TT vaccine was
considered to have an acceptable safety proﬁle.14 Advances in Preventive Medicine
In summary, a single dose of MenACWY-TT was shown
to be highly immunogenic for serogroups A, C, W-135, and
Y in toddlers, children, adolescents, and young adults and
had a clinically acceptable safety proﬁle. A Marketing Au-
thorizationApplicationwassubmittedtotheEuropeanMed-
icines Agency (EMA) on March 4, 2011 and is currently
under review. MenACWY-TT is not currently licensed in any
country.
3. Conclusions andPerspectives
Because of the severity of invasive meningococcal disease,
the rapidity with which it develops, and the high frequency
of long-term sequelae, development of eﬀective meningo-
coccal vaccines with clinically acceptable safety proﬁles is a
public health priority. The complete portfolio of conjugate
meningococcal vaccines developed by GSK Biologicals is de-
signed to respond to the global need with prioritisation in
infants and young children, followed by adolescents, the age
groups at highest risk. Two vaccines, using TT as carrier pro-
tein, were designed to help protect infants and young chil-
dren against meningococcal serogroup(s) C (and Y) and Hib
diseases in countries where these serogroups are major con-
tributors to meningococcal epidemiology. The ﬁrst vaccine
(Hib-MenC-TT) is presently approved in various countries
worldwide for use as three-dose primary vaccination in in-
fants and booster vaccination in toddlers or as one-dose
vaccinationintoddlerspreviouslyprimedwithHibbutna¨ ıve
for MenC. Primary vaccination resulted in immune priming
and induced immune memory as reﬂected by antibody per-
sistence and response to booster vaccination. The second
vaccine (Hib-MenCY-TT) adds serogroup Y antigen and an
application for licensure of this vaccine as four-dose immu-
nisation series in infants and toddlers is currently under
review by the US FDA. All primary hypotheses regarding the
noninferiority of both vaccines to licensed Hib (DTPa/Hib
combinations or Hib standalone vaccines) and monovalent
MenC conjugate vaccines were met. On the other hand, GSK
Biologicals has more recently evaluated an investigational
tetravalent conjugate meningococcal vaccine (MenACWY-
TT) designed to oﬀer protection against four of the six most
common serogroups worldwide for use in all age groups.
This vaccine was shown to be highly immunogenic in tod-
dlers, children, adolescents, and adults. All these vaccines
were shown to have an acceptable safety proﬁle, which was
comparable to licensed conjugate vaccines. As demonstrated
by the broad portfolio of meningococcal conjugate vaccines,
GSKremainscommittedtothedevelopmentofmeningococ-
cal vaccines, targeting the populations at greatest risk.
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